Physician

Rohan Gupta, DO

According to 2025 Medicare claims, Rohan Gupta, DO (NPI: 1326482860) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY CONSULTANTS PA (NPI: 1629021159; TIN: 752512142) and primary practice location at 76104-4611. Gupta is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Gupta's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 552 traditional Medicare patients, billed 285,912 HCPCS/CPT codes, and received $5,016,296 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,367 prescription claims across 349 beneficiaries totaling $5,891,641 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 77 claims. Open Payments data shows 62 records totaling $33,937. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $972 to $5,016,296. Similarly, Part D prescription costs have moved sharply higher in recent years, from $5,756 to $5,891,641. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	13	14	$972
2018	N/R	N/R	N/R
2019	198	18,234	$197,513
2020	469	111,134	$1,692,066
2021	478	261,691	$2,502,347
2022	462	254,741	$3,068,212
2023	458	266,205	$4,919,397
2024	552	285,912	$5,016,296

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	27	104	$5,756
2016	29	67	$19,649
2017	55	130	$60,956
2018	38	130	$349,507
2019	72	243	$390,293
2020	149	953	$2,029,398
2021	200	1,456	$2,893,259
2022	272	1,691	$4,092,826
2023	294	1,979	$5,473,115
2024	349	2,367	$5,891,641

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	53	$9,960
2022	N/R	157	$60,747
2023	N/R	77	$7,670
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	233	1,190	$139
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	155	253	$133
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	218	391	$94
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	237	1,715	$92
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	180	373	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	79	2,135	$1,080,680
Pomalyst	Pomalidomide	49	1,372	$805,501
Calquence	Acalabrutinib Maleate	32	960	$433,454
Promacta	Eltrombopag Olamine	27	810	$377,592
Vonjo	Pacritinib Citrate	13	390	$329,530

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	62	$33,937	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rohan Gupta, DO?

Tedicare shows public-source Medicare data for Rohan Gupta, DO (NPI 1326482860), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rohan Gupta, DO have ACO affiliation data?

Rohan Gupta, DO is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Rohan Gupta, DO?

Rohan Gupta, DO is linked to ONCOLOGY-HEMATOLOGY CONSULTANTS PA (billing NPI 1629021159) in the available physician profile data.

Does Rohan Gupta, DO have Open Payments data?

Rohan Gupta, DO has 62 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.